742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients

Allison Boyd, Todd Walroth, Brett Hartman, Matthew Bjornstad, Alyssa Garelli, Leigh Spera, C. Grooms
{"title":"742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients","authors":"Allison Boyd, Todd Walroth, Brett Hartman, Matthew Bjornstad, Alyssa Garelli, Leigh Spera, C. Grooms","doi":"10.1093/jbcr/irad045.216","DOIUrl":null,"url":null,"abstract":"\n \n \n Previous studies have found that standard dose enoxaparin is inadequate in achieving goal prophylactic anti-Xa levels in burn patients. A new venous thromboembolism (VTE) prophylaxis protocol was implemented at our institution (Table 1). The objective of this study was to assess the efficacy and safety of the updated VTE prophylaxis protocol to determine if goal anti-Xa levels can be achieved earlier compared to the previous enoxaparin dosing protocol.\n \n \n \n This was a retrospective cohort study evaluating a historic protocol group from 3/1/21 to 5/31/21 and a new protocol group from 10/1/21 to 12/31/21. Revisions were made to the new protocol group and evaluated from 7/1/22 to 8/31/22. Adult patients admitted with cutaneous and/or inhalation burn who received enoxaparin for VTE prophylaxis and had anti-Xa monitoring were included. The primary endpoint was protocol efficacy defined as percentage of initial anti-Xa levels within goal range and time to goal anti-Xa level. Secondary endpoints included protocol adherence, rate of VTE occurrence, number of missed or held doses if VTE occurred, correlation to published enoxaparin dosing equations in burn patients, and bleeding events.\n \n \n \n Results can be found in Table 2. The median (IQR) initial anti-Xa level in the historical (n=29) vs. new protocol group (n=22) was 0.09 (0.04-0.14) units/mL vs. 0.15 (0.10-0.19) units/mL (p=0.036). After adjusting the BMI cutoff in the new protocol from 40 kg/m2 to 35 kg/m2, the median initial anti-Xa was 0.16 (0.12-0.22) units/mL vs. 0.24 (0.19-0.28) units/mL (p=0.018). The mean ± SD time for patients to achieve goal anti-Xa level was 5 ± 3 days in the historical protocol and 5 ± 2 days in the new protocol group (p = 0.456). After protocol modification, the median time to goal anti-Xa level was 4 (3-6) days vs. 2 (1-3) days (p=0.002). No differences were noted in secondary outcomes.\n \n \n \n The new protocol resulted in a higher initial anti-Xa level with more patients within goal anti-Xa range which was reached in less time after modification of the BMI cutoff for weight-based dosing. The maximum anti-Xa level in the modified group was still within the prophylactic range with the new protocol, indicating no increase in supratherapeutic levels compared to previously utilized dosing strategies and there were no differences in major or minor bleeding events which supports its safety.\n \n \n \n This protocol can be replicated and utilized by other burn centers with the potential for a multicenter analysis and provides a framework for developing standardized VTE prophylaxis dosing recommendations with enoxaparin in burn patients.\n \n","PeriodicalId":366612,"journal":{"name":"Journal of Burn Care & Research","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Burn Care & Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jbcr/irad045.216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Previous studies have found that standard dose enoxaparin is inadequate in achieving goal prophylactic anti-Xa levels in burn patients. A new venous thromboembolism (VTE) prophylaxis protocol was implemented at our institution (Table 1). The objective of this study was to assess the efficacy and safety of the updated VTE prophylaxis protocol to determine if goal anti-Xa levels can be achieved earlier compared to the previous enoxaparin dosing protocol. This was a retrospective cohort study evaluating a historic protocol group from 3/1/21 to 5/31/21 and a new protocol group from 10/1/21 to 12/31/21. Revisions were made to the new protocol group and evaluated from 7/1/22 to 8/31/22. Adult patients admitted with cutaneous and/or inhalation burn who received enoxaparin for VTE prophylaxis and had anti-Xa monitoring were included. The primary endpoint was protocol efficacy defined as percentage of initial anti-Xa levels within goal range and time to goal anti-Xa level. Secondary endpoints included protocol adherence, rate of VTE occurrence, number of missed or held doses if VTE occurred, correlation to published enoxaparin dosing equations in burn patients, and bleeding events. Results can be found in Table 2. The median (IQR) initial anti-Xa level in the historical (n=29) vs. new protocol group (n=22) was 0.09 (0.04-0.14) units/mL vs. 0.15 (0.10-0.19) units/mL (p=0.036). After adjusting the BMI cutoff in the new protocol from 40 kg/m2 to 35 kg/m2, the median initial anti-Xa was 0.16 (0.12-0.22) units/mL vs. 0.24 (0.19-0.28) units/mL (p=0.018). The mean ± SD time for patients to achieve goal anti-Xa level was 5 ± 3 days in the historical protocol and 5 ± 2 days in the new protocol group (p = 0.456). After protocol modification, the median time to goal anti-Xa level was 4 (3-6) days vs. 2 (1-3) days (p=0.002). No differences were noted in secondary outcomes. The new protocol resulted in a higher initial anti-Xa level with more patients within goal anti-Xa range which was reached in less time after modification of the BMI cutoff for weight-based dosing. The maximum anti-Xa level in the modified group was still within the prophylactic range with the new protocol, indicating no increase in supratherapeutic levels compared to previously utilized dosing strategies and there were no differences in major or minor bleeding events which supports its safety. This protocol can be replicated and utilized by other burn centers with the potential for a multicenter analysis and provides a framework for developing standardized VTE prophylaxis dosing recommendations with enoxaparin in burn patients.
烧伤患者应用依诺肝素预防静脉血栓栓塞和抗xa水平的评价
先前的研究发现,标准剂量的依诺肝素不足以达到烧伤患者预防性抗xa水平的目标。我们机构实施了一项新的静脉血栓栓塞(VTE)预防方案(表1)。本研究的目的是评估更新后的VTE预防方案的有效性和安全性,以确定与之前的依诺肝素给药方案相比,是否可以更早地达到目标抗xa水平。这是一项回顾性队列研究,评估了21年3月1日至5月31日的历史方案组和21年10月1日至12月31日的新方案组。对新方案组进行了修订,并从7/1/22至8/31/22进行了评估。纳入接受依诺肝素预防静脉血栓栓塞并进行抗xa监测的皮肤和/或吸入性烧伤入院的成年患者。主要终点是方案疗效,定义为目标范围内初始抗xa水平的百分比和达到目标抗xa水平的时间。次要终点包括方案依从性、静脉血栓栓塞发生率、静脉血栓栓塞发生时遗漏或保留剂量的数量、与烧伤患者已发表的依诺肝素剂量方程的相关性以及出血事件。结果见表2。历史组(n=29)与新方案组(n=22)的初始抗xa水平中位数(IQR)为0.09(0.04-0.14)单位/mL vs 0.15(0.10-0.19)单位/mL (p=0.036)。在将新方案中的BMI临界值从40 kg/m2调整到35 kg/m2后,初始抗xa中位数为0.16(0.12-0.22)单位/mL vs. 0.24(0.19-0.28)单位/mL (p=0.018)。患者达到目标抗xa水平的平均±SD时间在历史方案组为5±3天,在新方案组为5±2天(p = 0.456)。方案修改后,达到目标抗xa水平的中位时间为4(3-6)天vs. 2(1-3)天(p=0.002)。次要结局无显著差异。新方案导致更高的初始抗xa水平,在修改体重给药的BMI截止时间后,更多的患者在更短的时间内达到目标抗xa范围。修改组的最大抗xa水平仍在新方案的预防范围内,表明与先前使用的剂量策略相比,超治疗水平没有增加,并且在大出血事件和小出血事件方面没有差异,这支持了其安全性。该方案可被其他烧伤中心复制和利用,具有多中心分析的潜力,并为烧伤患者使用依诺肝素制定标准化静脉血栓栓塞预防剂量建议提供了框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书